Insilico Medicine, the Hong Kong-listed biotech firm, is exploring a secondary listing on the Abu Dhabi Securities Exchange, according to sources familiar with the matter. This move would mark a significant milestone as the company would become the first non-Gulf entity to list shares on a regional exchange in the Middle East, opening new avenues for international investors.

The firm, which went public in Hong Kong just last December, has held preliminary discussions about potentially listing shares in Abu Dhabi as early as this year. Sources requested anonymity as the information remains confidential while the company evaluates its expansion options in the Middle Eastern market.

This potential listing represents a strategic geographic expansion for Insilico Medicine and could enhance its access to Middle Eastern capital markets. For Abu Dhabi, securing a prominent international biotech company would strengthen its position as a financial hub in the region, demonstrating the exchange's growing attractiveness to global healthcare innovators seeking diverse funding sources beyond traditional markets.